Show simple item record

dc.creatorKalra, Rajkumar
dc.creatorTomar, Dhanendra
dc.creatorMeena, Avtar Singh
dc.creatorKandimalla, Ramesh
dc.date.accessioned2020-08-24T17:30:05Z
dc.date.available2020-08-24T17:30:05Z
dc.date.issued2020-07-07
dc.identifier.citationKalra, R.S.; Tomar, D.; Meena, A.S.; Kandimalla, R. SARS-CoV-2, ACE2, and Hydroxychloroquine: Cardiovascular Complications, Therapeutics, and Clinical Readouts in the Current Settings. Pathogens 2020, 9, 546.
dc.identifier.issn2076-0817
dc.identifier.doihttp://dx.doi.org/10.34944/dspace/237
dc.identifier.urihttp://hdl.handle.net/20.500.12613/253
dc.description.abstractThe rapidly evolving coronavirus disease 2019 (COVID-19, caused by severe acute respiratory syndrome coronavirus 2- SARS-CoV-2), has greatly burdened the global healthcare system and led it into crisis in several countries. Lack of targeted therapeutics led to the idea of repurposing broad-spectrum drugs for viral intervention. In vitro analyses of hydroxychloroquine (HCQ)’s anecdotal benefits prompted its widespread clinical repurposing globally. Reports of emerging cardiovascular complications due to its clinical prescription are revealing the crucial role of angiotensin-converting enzyme 2 (ACE2), which serves as a target receptor for SARS-CoV-2. In the present settings, a clear understanding of these targets, their functional aspects and physiological impact on cardiovascular function are critical. In an up-to-date format, we shed light on HCQ’s anecdotal function in stalling SARS-CoV-2 replication and immunomodulatory activities. While starting with the crucial role of ACE2, we here discuss the impact of HCQ on systemic cardiovascular function, its associated risks, and the scope of HCQ-based regimes in current clinical settings. Citing the extent of HCQ efficacy, the key considerations and recommendations for the use of HCQ in clinics are further discussed. Taken together, this review provides crucial insights into the role of ACE2 in SARS-CoV-2-led cardiovascular activity, and concurrently assesses the efficacy of HCQ in contemporary clinical settings.
dc.format.extent35 pages
dc.languageEnglish
dc.language.isoeng
dc.relation.ispartofCOVID-19 Research
dc.relation.haspartPathogens, Vol. 9, Issue 7
dc.relation.isreferencedbyMDPI
dc.rightsAttribution CC BY
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/
dc.subjectSARS-CoV-2
dc.subjectCOVID-19
dc.subjectACE2
dc.subjectHydroxychloroquine
dc.subjectCardiovascular system
dc.subjectCardiovascular disease (CVD)
dc.subjectTherapeutics
dc.titleSARS-CoV-2, ACE2, and Hydroxychloroquine: Cardiovascular Complications, Therapeutics, and Clinical Readouts in the Current Settings
dc.typeText
dc.type.genreJournal article
dc.contributor.groupCenter for Translational Medicine (Temple University)
dc.relation.doihttps://doi.org/10.3390/pathogens9070546
dc.ada.noteFor Americans with Disabilities Act (ADA) accommodation, including help with reading this content, please contact scholarshare@temple.edu
dc.description.schoolcollegeLewis Katz School of Medicine
dc.creator.orcid0000-0002-3144-7257
dc.temple.creatorTomar, Dhanendra
refterms.dateFOA2020-08-24T17:30:05Z


Files in this item

Thumbnail
Name:
Tomar-JournalArticle-2020.pdf
Size:
1.942Mb
Format:
PDF

This item appears in the following Collection(s)

Show simple item record

Attribution CC BY
Except where otherwise noted, this item's license is described as Attribution CC BY